Rotundifuran Induces Ferroptotic Cell Death and Mitochondria Permeability Transition in Lung Cancer Cells

Rotundifuran (RF), a potent anti-inflammatory and anti-cancer compound, is a natural compound predominantly present in Vitex Rotundifolia. Herein, we investigated the effects of RF on the growth of lung cancer cells. Our findings suggested that RF inhibits cell growth, highlighting its potential as a therapeutic agent for cancer treatment. Interestingly, we observed that cell growth inhibition was not due to apoptosis, as caspases were not activated and DNA fragmentation did not occur. Furthermore, we found that intracellular vacuoles and autophagy were induced, but RF-induced cell death was not affected when autophagy was inhibited. This prompted us to investigate other possible mechanisms underlying cell growth inhibition. Through a cDNA chip analysis, we confirmed changes in the expression of ferroptosis-related genes and observed lipid peroxidation. We further examined the effect of ferroptosis inhibitors and found that they alleviated cell growth inhibition induced by RF. We also observed the involvement of calcium signaling, ROS accumulation, and JNK signaling in the induction of ferroptosis. Our findings suggested that RF is a potent anti-cancer drug and further studies are needed to validate its clinal use.

Medienart:

E-Artikel

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Zur Gesamtaufnahme - volume:12

Enthalten in:

Biomedicines - 12(2024), 3 vom: 05. März

Sprache:

Englisch

Beteiligte Personen:

Kang, Myung-Ji [VerfasserIn]
Moon, Dong-Oh [VerfasserIn]
Park, Ji-Yoon [VerfasserIn]
Kim, Namho [VerfasserIn]
Lee, Su Hyeon [VerfasserIn]
Ryu, Hyung Won [VerfasserIn]
Huh, Yang Hoon [VerfasserIn]
Lee, Hyun-Sun [VerfasserIn]
Kim, Mun-Ock [VerfasserIn]

Links:

Volltext

Themen:

Ferroptosis
Journal Article
Mitochondria permeability transition (MPT)
Reactive oxygen species (ROS)
Rotundifuran

Anmerkungen:

Date Revised 30.03.2024

published: Electronic

Citation Status PubMed-not-MEDLINE

doi:

10.3390/biomedicines12030576

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM370297326